Stock Detail
GENTIUM SPA - ADS REPRESENTS ORDINARY SHARES
Biotechnology
GENT @ Yahoo Finance | GENT Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $5.75 | $6.02 | $-0.28 | -4.64% | 0.00 | $6.03 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $6.00 | $5.56 | 28,840 | 86.06M | 75,082 | 14.76 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 6.24 | 6.00 | 5.78 | 5.54 | 5.32 |
Stock Profile
Gentium S.p.A., a biopharmaceutical company, engages in the research, development, and manufacture of drugs to treat and prevent various vascular diseases and conditions related to cancer and cancer treatments. It manufactures defibrotide to treat deep vein thrombosis, and to treat and prevent various vascular diseases with risk of thrombosis. The company also conducts Phase III clinical trials of defibrotide to treat Veno-Occlusive Disease with multiple-organ failure; and phase I/II clinical trials to treat multiple myeloma. In addition, Gentium offers urokinase, which is used to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms; and heparin calcium, which is used for the treatment of certain types of lung, blood vessel, and heart disorders, and administration during or after certain types of surgery, such as open heart and bypass surgeries. Further, it manufactures sulglicotide, which is intended to treat peptic ulcers. Additionally, Gentium develops a formulation of the drug mesalazine to treat inflammatory bowel disease. It sells its products primarily in Italy. The company was founded in 1993 as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in 2001. Gentium is based in Villa Guardia, Italy.